uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases.
We are advancing a focused pipeline of innovative gene therapies. We are currently conducting a pivotal phase 3 trial in our lead indication, hemophilia B, and will initiate a Phase I/II trial in Huntington’s disease in the second half of 2019. Our pipeline of adeno-associated virus (AAV)-based gene therapies has been developed using an innovative technology platform, supported by industry-leading proprietary commercial-grade manufacturing capabilities.
Amsterdamse Science & Innovation Awards 2021 voor digitale urineweegschaal, nanofolie en dyslexiespel voor kinderen In NEMO Amsterdam zijn voor de 15e keer de jaarlijkse Innovation Awards uitgereikt. De innovatieprijzen zijn een initiatief van de Innovation Exchange Amsterdam (IXA). IXA bekroont met de Awards vernieuwende ideeën om de samenleving te verbeteren van jonge wetenschappers, allemaal verbonden […]News
UvA’ most recent spinout SolarFoil aims to increase greenhouse productivity by optimizing sunlight to increase crop yields. In doing so, the use of SolarFoil aims to reduce the use of energy- hungry artificial lighting and make horticulture more sustainable. The team behind SolarFoil, professor Peter Schall and PhD Arnon Lesage of the UvA’ Institute of […]News
The pre-finalists for the Innovation Award 2023, the Amsterdam competition for innovative ideas that contribute to a better world, are now selected! Topics that you will see this year are most definitely novel uses of AI, for instance in academia and in health, clever notions on how to deal with the effects of climate change, […]News